APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia. [PDF]
Antimicrob Agents Chemother, 2019 Coccidioidomycosis is a systemic fungal infection caused by the inhalation of the arthroconidia of either of two closely related dimorphic fungi, Coccidioides immitis and C. posadasii, that are endemic in the southwestern United States and other areas in
Viriyakosol S +7 more
europepmc +7 more sources
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. [PDF]
Antimicrob Agents Chemother, 2019 APX001, the prodrug of APX001A, is a first-in-class antifungal agent that has a potent activity against Aspergillus fumigatus. The goal of current study was to determine the pharmacodynamic (PD) index and target of APX001 in an immunocompromised murine ...
Zhao M +6 more
europepmc +5 more sources
726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection [PDF]
Open Forum Infect Dis, 2019 Background Mucormycosis is a life-threatening infection that predominantly occurs in immunocompromised hosts. The antifungal APX001A (manogepix) inhibits Gwt1, an enzyme required for the conserved glycosylphosphatidyl inositol (GPI) post-translational ...
Gebremariam T +6 more
europepmc +4 more sources
Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis. [PDF]
Antimicrob Agents Chemother, 2018 APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections.
Zhao Y +8 more
europepmc +4 more sources
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. [PDF]
Antimicrob Agents Chemother, 2018 Cryptococcal meningitis (CM), caused primarily by Cryptococcus neoformans, is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates remain high despite current therapies ...
Shaw KJ +12 more
europepmc +4 more sources
Absorption, Distribution, and Excretion of 14C-APX001 after Single-Dose Administration to Rats and Monkeys [PDF]
Open Forum Infectious Diseases, 2017 Background APX001 is a small-molecule therapeutic agent in clinical development for the treatment of invasive fungal infections (IFI). Methods The absorption, distribution and excretion profiles of [14C]APX001-derived radioactivity were determined in ...
R. Mansbach +4 more
exaly +3 more sources
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects [PDF]
Open Forum Infectious Diseases, 2017 Administered by Intravenous Infusion to Healthy Subjects M. R. Hodges 1*, E. Ople 1, K. J. Shaw 1, R. Mansbach 1, S. van Marle 2, E. van Hoogdalem 2, P. Wedel 1, and W.
M. Hodges +7 more
exaly +3 more sources
1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis [PDF]
Open Forum Infect Dis, 2019 Background Candida auris is an emerging pathogen associated with antifungal resistance and high mortality. The novel antifungal manogepix (APX001A) prevents glycosylphosphatidylinositol-anchored protein maturation through inhibition of the inositol ...
Wiederhold N +7 more
europepmc +4 more sources
Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability [PDF]
Open Forum Infectious Diseases, 2017 Karen Joy Shaw
exaly +3 more sources
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. [PDF]
J Antimicrob Chemother, 2023 Objectives Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs).
Cornely OA +8 more
europepmc +2 more sources